Immune Biomarker Study for Head and Neck Cancer

RecruitingOBSERVATIONAL
Enrollment

1,100

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Head and Neck CancerOral Cavity CancerOropharyngeal CancerHypopharyngeal CancerLaryngeal Cancer
Interventions
OTHER

Sampling

This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.

Trial Locations (3)

91054

RECRUITING

ENT - Head and Neck Surgery Department, Erlangen

RECRUITING

Maxillo-Facial-Surgery Department, Erlangen

RECRUITING

Radiation Oncology Department, Erlangen

All Listed Sponsors
collaborator

University Hospital Erlangen

OTHER

collaborator

University Hospital Regensburg

OTHER

collaborator

University Hospital Augsburg

OTHER

lead

University of Erlangen-Nürnberg Medical School

OTHER